Eli Lilly and Company (NYSE:LLY) Stake Lifted by Oakworth Capital Inc.

Oakworth Capital Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,633 shares of the company’s stock after acquiring an additional 181 shares during the period. Oakworth Capital Inc.’s holdings in Eli Lilly and Company were worth $2,118,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares during the period. Morgan Stanley lifted its holdings in Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Northern Trust Corp lifted its holdings in Eli Lilly and Company by 3.6% during the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the last quarter. Norges Bank bought a new position in Eli Lilly and Company during the 4th quarter valued at about $3,416,206,000. Finally, International Assets Investment Management LLC lifted its holdings in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.3 %

LLY traded up $2.46 during mid-day trading on Wednesday, reaching $749.20. 2,594,489 shares of the stock were exchanged, compared to its average volume of 3,078,969. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $711.86 billion, a PE ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The company has a 50 day moving average price of $763.51 and a two-hundred day moving average price of $657.01. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm earned $2.09 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Analyst Ratings Changes

LLY has been the subject of several research reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday. Finally, Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.